Charmacy Pharmaceutical Co., Ltd. Class H Statistics
Want to see HK:2289 full AI Analyst Report?
Charmacy Pharmaceutical Co., Ltd. Class H (2289) Stock Statistics & Valuation Metrics
Total Valuation
Charmacy Pharmaceutical Co., Ltd. Class H has a market cap or net worth of HKD 592.92M. The enterprise value is HKD 2.75B.
- Market Cap
- HKD 592.92M
- Enterprise Value
- HKD 2.75B
Share Statistics
Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 108,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Charmacy Pharmaceutical Co., Ltd. Class H’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 1.80%.
- Return on Equity (ROE)
- 0.08
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 1.80%
- Return on Capital Employed (ROCE)
- 0.10
- Revenue Per Employee
- 5.30M
- Profits Per Employee
- 55.95K
- Employee Count
- 827
- Asset Turnover
- 1.11
- Inventory Turnover
- 5.08
Valuation Ratios
The current PE Ratio of Charmacy Pharmaceutical Co., Ltd. Class H is 10.84. Charmacy Pharmaceutical Co., Ltd. Class H’s PEG ratio is -2.44.
- PE Ratio
- 10.84
- PS Ratio
- 0.11
- PB Ratio
- 0.83
- Price to FCF
- 1.61
- Price to Operating Cash Flow
- 1.58
- PEG Ratio
- -2.44
Income Statement
In the last 12 months, Charmacy Pharmaceutical Co., Ltd. Class H had revenue of 4.38B and earned 46.27M in profits. Earnings per share was 0.43.
- Revenue
- 4.38B
- Gross Profit
- 336.01M
- Operating Income
- 68.10M
- Pretax Income
- 64.31M
- Net Income
- 46.27M
- EBITDA
- 166.97M
- Earnings Per Share (EPS)
- 0.43
Cash Flow
In the last 12 months, operating cash flow was 317.99M and capital expenditures -6.05M, giving a free cash flow of 311.94M billion.
- Operating Cash Flow
- 317.99M
- Free Cash Flow
- 311.94M
- Free Cash Flow per Share
- 2.89
Dividends & Yields
Charmacy Pharmaceutical Co., Ltd. Class H pays an annual dividend of HKD 0.49, resulting in a dividend yield of 6.26%
- Dividend Per Share
- HKD 0.49
- Dividend Yield
- 6.26%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 61.95%
- Earnings Yield
- 9.35%
Stock Price Statistics
- Beta
- -0.25
- 52-Week Price Change
- -22.13%
- 50-Day Moving Average
- 5.49
- 200-Day Moving Average
- 5.73
- Relative Strength Index (RSI)
- 9.18
- Average Volume (3m)
- 32.38K
Important Dates
Charmacy Pharmaceutical Co., Ltd. Class H upcoming earnings date is Mar 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Mar 26, 2027
- Ex-Dividend Date
- May 26, 2025
Financial Position
Charmacy Pharmaceutical Co., Ltd. Class H as a current ratio of 1.09, with Debt / Equity ratio of 338.89%
- Current Ratio
- 1.09
- Quick Ratio
- 0.84
- Debt to Market Cap
- 2.92
- Net Debt to EBITDA
- 8.00
- Interest Coverage Ratio
- 1.11
Taxes
In the past 12 months, Charmacy Pharmaceutical Co., Ltd. Class H has paid 18.04M in taxes.
- Income Tax
- 18.04M
- Effective Tax Rate
- 0.28
Enterprise Valuation
Charmacy Pharmaceutical Co., Ltd. Class H EV to EBITDA ratio is 12.86, with an EV/FCF ratio of 6.62.
- EV to Sales
- 0.44
- EV to EBITDA
- 12.86
- EV to Free Cash Flow
- 6.62
- EV to Operating Cash Flow
- 6.49
Balance Sheet
Charmacy Pharmaceutical Co., Ltd. Class H has HKD 530.00M in cash and marketable securities with HKD 2.09B in debt, giving a net cash position of -HKD 1.56B billion.
- Cash & Marketable Securities
- HKD 530.00M
- Total Debt
- HKD 2.09B
- Net Cash
- -HKD 1.56B
- Net Cash Per Share
- -HKD 14.46
- Tangible Book Value Per Share
- HKD 4.94
Margins
Gross margin is 7.24%, with operating margin of 2.09%, and net profit margin of 1.01%.
- Gross Margin
- 7.24%
- Operating Margin
- 2.09%
- Pretax Margin
- 1.42%
- Net Profit Margin
- 1.01%
- EBITDA Margin
- 3.43%
- EBIT Margin
- 2.69%
Analyst Forecast
The average price target for Charmacy Pharmaceutical Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 14.25%
- EPS Growth Forecast
- 0.83%
Scores
- Smart Score
- 5
- AI Score
- 47

